Adempas
The medicinal product has been authorised by the European Commission (EC) via centralised procedure in all EU Member States, based on the European Medicines Agency (EMA) experts' opinion.
Name | Adempas |
---|---|
Active Substance | riocigvat |
Prescription | na recept |
Type of prescription | ograničeni recept |
Distribution | u ljekarni |
ATC Code | C02KX05 |
Medicinal product marketed in the Croatia | Da |
Summary of product characteristics (SmPC), labelling and package leaflet (PL) | download |
Link to the European Medicines Agency's (EMA) product information | download |
Link to the European Commission's (EC) decisions | download |
Direct Healthcare Professional Communication
Name | Date | Download |
---|---|---|
Pismo zdravstvenim radnicima o novoj kontraindikaciji lijeka Adempas (riocigvat) za bolesnike s plućnom hipertenzijom povezanom s idiopatskim intersticijskim pneumonijama (PH IIP) | 04.07.2016 | Bayer d.o.o. i Merck Sharp & Dohme d.o.o. |